Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · KYNTRA BIO, INC. (KYNB)

Kyntra Bio receives Nasdaq delisting determination; stock stays listed pending hearing

Negative Impact 5 of 5 legal/regulatory Written later

Nasdaq's Listing Qualifications Staff determined to delist Kyntra Bio's common stock after the company did not show compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. Kyntra Bio has requested a hearing before a Nasdaq Hearings Panel, and the stock will keep trading under KYNB while the Panel decides, so shareholders face continued uncertainty over the listing.

Key points

  • Staff determination letter dated September 30, 2026; compliance deadline was September 29, 2026
  • Company timely requested a Nasdaq Hearings Panel review, which stays the suspension and delisting
  • Extension period could be up to 180 days from the Staff determination under Listing Rule 5815(c)(1)(A)
  • Company previously received a April 2, 2026 notice on total assets, total revenue and stockholders' equity or market value standards; no assurance the Panel will grant continued listing

The filing

CompanyKYNTRA BIO, INC. (KYNB)
Form8-K, current report
Filed with the SECOct 6, 2026, 4:05 PM ET
Accession number0001193125-26-415545

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.